| answer text |
<p>Sativex is licensed for the treatment of moderate to severe spasticity in multiple
sclerosis (MS). It is normally prescribed on the National Health Service by a specialist
doctor with experience of treating MS spasticity – consultant neurologists, consultant
rehabilitation specialists and consultant pain specialists.</p><p> </p><p>When the
National Institute for Health and Care Excellence (NICE) published its guideline on
the treatment of adults with MS in 2014, it recommended that Sativex should not be
offered as an option to treat spasticity in people with MS because it is not a cost
effective treatment. NICE is responsible for determining whether its guidance should
be updated following the publication of any significant new evidence.</p>
|
 |
